Profile data is unavailable for this security.
About the company
Henan Taloph Pharmaceutical Stock Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company operates four segments. Pharmaceutical Manufacturing segment is mainly engaged in pharmaceutical preparations and Chinese herbal medicine slices business. Its products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Xiaoer Qingre Zhike oral liquid, Xiaoer Tuire oral liquid, Danshen oral liquid, Shengmaiyin, Fufang Yimu oral liquid, and various Chinese herbal medicine slices. Pharmaceutical and Medicinal Materials Circulation segment is mainly engaged in fresh processing business and traceable medicinal materials trading. Pharmaceutical Research and Development Services segment mainly provides technical services such as preclinical pharmaceutical research, clinical contract research organization (CRO) research, and registration application. Other segment is mainly engaged in investment business.
- Revenue in CNY (TTM)1.97bn
- Net income in CNY89.38m
- Incorporated1998
- Employees2.35k
- LocationHenan Taloph Pharmaceutical Stock Co LtdNo. 8Jinsuo RoadHi-Tech Industrial Development ZoneZHENGZHOU 450001ChinaCHN
- Phone+86 37 167992262
- Fax+86 37 167993600
- Websitehttp://www.taloph.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frontier Biotechnologies Inc | 122.86m | -316.34m | 2.72bn | 395.00 | -- | 2.30 | -- | 22.16 | -0.8445 | -0.8445 | 0.328 | 3.16 | 0.057 | 1.43 | 2.91 | 311,049.00 | -14.67 | -14.05 | -17.86 | -15.78 | 31.82 | 2.35 | -257.47 | -450.08 | 2.11 | -- | 0.2763 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.24bn | 20.30m | 2.92bn | 2.35k | 153.22 | 1.34 | -- | 2.36 | 0.087 | 0.087 | 5.70 | 9.92 | 0.267 | 1.18 | 4.91 | 525,730.80 | 0.5164 | 4.94 | 0.7951 | 7.83 | 29.01 | 35.39 | 1.93 | 13.71 | 0.7203 | 4.44 | 0.4199 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
| Henan Taloph Pharmaceutical Stock Co Ltd | 1.97bn | 89.38m | 2.94bn | 2.35k | 33.87 | 1.87 | -- | 1.50 | 0.1515 | 0.1515 | 3.39 | 2.74 | 0.5571 | 2.93 | 2.06 | 836,256.80 | 2.67 | 0.272 | 5.80 | 0.4981 | 27.64 | 27.97 | 4.79 | 0.5501 | 0.8146 | 2.65 | 0.3911 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 2.40bn | -235.62m | 2.95bn | 5.51k | -- | 1.12 | -- | 1.23 | -0.2975 | -0.2975 | 3.03 | 3.34 | 0.5288 | 1.52 | 13.04 | 435,209.10 | -5.39 | 0.8648 | -6.97 | 1.18 | 61.81 | 74.87 | -10.19 | 1.45 | 1.36 | -9.98 | 0.2375 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 120.07m | -467.96m | 3.11bn | 205.00 | -- | 5.48 | -- | 25.92 | -0.7142 | -0.7142 | 0.1833 | 0.8664 | 0.1067 | 0.623 | 4.76 | 585,689.70 | -41.57 | -- | -45.49 | -- | 81.88 | -- | -389.75 | -- | 6.43 | -- | 0.3488 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| ChengDu Sheng Nuo Biotec Co Ltd | 481.63m | 92.49m | 3.14bn | 1.13k | 33.83 | 3.42 | -- | 6.51 | 0.8279 | 0.8279 | 4.31 | 8.20 | 0.3401 | 0.862 | 3.96 | 426,977.70 | 6.52 | 7.47 | 8.67 | 9.44 | 59.92 | 70.52 | 19.17 | 15.82 | 0.8466 | 13.35 | 0.32 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.00m | 0.35% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2024 | 1.46m | 0.26% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 909.00k | 0.16% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 719.70k | 0.13% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 622.73k | 0.11% |
| Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2024 | 522.00k | 0.09% |
| Bodao Fund Management Co Ltd.as of 30 Jun 2024 | 204.50k | 0.04% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 91.77k | 0.02% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 75.60k | 0.01% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 69.50k | 0.01% |
